IOBT vs. ABEO, ONCT, GNPX, TNXP, LVTX, MBIO, ALZN, DMAC, ASLN, and MDNA
Should you be buying IO Biotech stock or one of its competitors? The main competitors of IO Biotech include Abeona Therapeutics (ABEO), Oncternal Therapeutics (ONCT), Genprex (GNPX), Tonix Pharmaceuticals (TNXP), LAVA Therapeutics (LVTX), Mustang Bio (MBIO), Alzamend Neuro (ALZN), DiaMedica Therapeutics (DMAC), ASLAN Pharmaceuticals (ASLN), and Medicenna Therapeutics (MDNA). These companies are all part of the "pharmaceutical preparations" industry.
IO Biotech vs.
IO Biotech (NASDAQ:IOBT) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability, dividends and community ranking.
IO Biotech has a beta of -0.61, indicating that its share price is 161% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
In the previous week, IO Biotech had 11 more articles in the media than Abeona Therapeutics. MarketBeat recorded 17 mentions for IO Biotech and 6 mentions for Abeona Therapeutics. IO Biotech's average media sentiment score of 0.73 beat Abeona Therapeutics' score of 0.14 indicating that IO Biotech is being referred to more favorably in the media.
53.2% of IO Biotech shares are held by institutional investors. Comparatively, 37.7% of Abeona Therapeutics shares are held by institutional investors. 11.6% of IO Biotech shares are held by insiders. Comparatively, 2.4% of Abeona Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
IO Biotech's return on equity of -43.58% beat Abeona Therapeutics' return on equity.
Abeona Therapeutics received 503 more outperform votes than IO Biotech when rated by MarketBeat users. However, 88.89% of users gave IO Biotech an outperform vote while only 71.27% of users gave Abeona Therapeutics an outperform vote.
IO Biotech currently has a consensus target price of $10.50, suggesting a potential upside of 412.20%. Abeona Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 1,566.67%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than IO Biotech.
IO Biotech has higher earnings, but lower revenue than Abeona Therapeutics. IO Biotech is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
IO Biotech beats Abeona Therapeutics on 9 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IOBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
IO Biotech Competitors List